Rayonier Inc. reported a Q4 profit of $25.9 million, or 16 cents per share, exceeding expectations. Revenue for the quarter reached $117.5 million, also surpassing forecasts. For the year, profit totaled $474.4 million on $484.5 million revenue.
Ameren Corp. reported a Q4 profit of $252 million, or 92 cents per share, exceeding expectations but with revenue of $1.78 billion falling short of forecasts. Full-year earnings are projected between $5.25 to $5.45 per share.
U.S. and world stock indices showed mixed results, with the Dow Jones Industrial average declining, while the Dow Jones Utilities and FT-100 saw gains. The Nasdaq and S&P500 also experienced slight decreases.
This is a paid press release. Contact the press release distributor directly with any inquiries.
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors ==============================================================================
Cathie Wood Bets Big On Musk As SpaceX–xAI Merger Anchors 17.5% Of ARK Fund ===========================================================================
Rishabh Mishra
Thu, February 12, 2026 at 7:31 AM GMT+9 3 min read
TG Therapeutics will host a conference call on February 26, 2026, at 8:30 AM ET to discuss their Q4 and full-year 2025 financial results and business outlook for 2026. CEO Michael S. Weiss will lead the call.
RBC Capital's Lori Calvasina asserts that recent tariff changes will not affect the long-term U.S. equity market outlook, as companies can adapt to trade policy shifts. Short-term monitoring is advised, yet the changes are deemed inconsequential overall.
Merck plans to separate its cancer and non-cancer divisions to mitigate potential losses from Keytruda's patent expiration in 2028, as it seeks new growth opportunities amid increasing competition.
Bitdeer’s $62m Bitcoin liquidation ‘not a concern’ as miner eyes land acquisitions ==================================================================================
Bitdeer has sold off the rest of its Bitcoin. Illustration: Andrés Tapia; Source:
This is a paid press release. Contact the press release distributor directly with any inquiries.
Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with
USDT Triggers Rare Signal Last Seen at 2022 Bitcoin Bottom, but Rebound May Be Slower =====================================================================================
Prashant Jha
Mon, February 23, 2026 at 8:47 PM GMT+9 4 min read